Oct 10, 2024
Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit
Oct 03, 2024
Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast Cancer
Sep 24, 2024
Immutep Receives A$3.6 million R&D Tax Incentive from French Government
Sep 17, 2024
New Data to be Presented from EFTISARC-NEO Phase II Evaluating Novel Triple Combination including Immutep’s Efti in Soft Tissue Sarcoma
Sep 15, 2024
Immutep’s Efti in Combination with MSD’s KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer
Aug 20, 2024
Immutep Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO Congress 2024
Aug 14, 2024
Immutep Announces First Participant Dosed in Phase I Study of IMP761, a First in Class Agonist LAG-3 Antibody
Aug 07, 2024
Immutep to Participate in Upcoming Investor Conferences
Jul 31, 2024
Immutep Quarterly Activities Report Q4 FY24
Jul 21, 2024
Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer
Jul 17, 2024
Immutep Receives Regulatory Clearance for Phase I Study of First-in-Class LAG-3 Agonist Antibody Designed to Treat Autoimmune Diseases
Jul 11, 2024
Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression
